IntraCellular Z Score
ITCI  Stock  USD 57.02 2.17 3.67% 
IntraCellular  Z Score 
IntraCellular Z Score Analysis
IntraCellular Ther's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2021  2022 (projected)  
Interest Expense  33.1 K  33.97 K 
Gross Profit  75.77 M  81.75 M 
Z Score  =  Sum Of   5 Factors 
 
 
 
 

IntraCellular Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for IntraCellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since IntraCellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IntraCellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IntraCellular Ther's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
According to the company's disclosures, IntraCellular Ther has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturersâ€”Specialty & Generic (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.
IntraCellular Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IntraCellular Ther's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IntraCellular Ther could also be used in its relative valuation, which is a method of valuing IntraCellular Ther by comparing valuation metrics of similar companies.IntraCellular Ther is currently under evaluation in z score category among related companies.
IntraCellular Ther Current Valuation Drivers
We derive many important indicators used in calculating different scores of IntraCellular Ther from analyzing IntraCellular Ther's financial statements. These drivers represent accounts that assess IntraCellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IntraCellular Ther's important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (2 M)  (2.13 M)  (447.64 K)  (591.09 K)  (554.93 K)  (598.74 K)  
Revenue Per Employee  7.85 K  5.02 K  184  59.4 K  163.68 K  176.6 K  
Average Assets  381.88 M  400.13 M  296.14 M  602.7 M  586.77 M  498.29 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (98.62 M)  (154.76 M)  (147.24 M)  (226.46 M)  (283.59 M)  (291.05 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (98.62 M)  (154.76 M)  (147.24 M)  (226.46 M)  (283.59 M)  (291.05 M)  
Earnings before Tax  (98.83 M)  (155.13 M)  (147.72 M)  (226.99 M)  (284.12 M)  (291.6 M)  
Average Equity  366.64 M  371.23 M  241.82 M  544.06 M  517.6 M  443.81 M  
Enterprise Value  737.94 M  553.56 M  1.82 B  2.28 B  4.18 B  4.51 B  
Free Cash Flow  (81.22 M)  (118.56 M)  (128.68 M)  (230.34 M)  (259.87 M)  (266.71 M)  
Invested Capital  419.49 M  265.96 M  130.47 M  648.16 M  368.21 M  332.89 M  
Invested Capital Average  333.71 M  306.89 M  193.88 M  423.85 M  451.48 M  372.11 M  
Market Capitalization  790.28 M  623.33 M  1.9 B  2.55 B  4.26 B  4.6 B  
Tangible Asset Value  471.49 M  357.21 M  251.19 M  717.31 M  489.92 M  435.39 M  
Working Capital  455.01 M  319.14 M  194.1 M  654.05 M  413.92 M  379.9 M 
IntraCellular Ther Institutional Holders
Institutional Holdings refers to the ownership stake in IntraCellular Ther that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of IntraCellular Ther's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in highprofile magazines, and presentations at investor conferences help move the stock higher, increasing IntraCellular Ther's value.Security Type  Shares  Value  
Victory Capital Management Inc  Common Shares  1.1 M  64.8 M  
Pictet Asset Management Sa  Common Shares  1.1 M  63.6 M  
Timessquare Capital Management Llc  Common Shares  800.8 K  45.7 M  
Gwk Investment Management Llc  Common Shares  583.6 K  33.3 M  
Nicholas Investment Partners Lp  Common Shares  434 K  24.8 M  
Skandinaviska Enskilda Banken Ab Publ  Common Shares  383.6 K  21.9 M  
Lisanti Capital Growth Llc  Common Shares  327.9 K  18.7 M 
IntraCellular Fundamentals
Return On Equity  (43.21) %  
Return On Asset  (24.72) %  
Profit Margin  (294.89) %  
Operating Margin  (295.91) %  
Current Valuation  4.91 B  
Shares Outstanding  94.32 M  
Shares Owned by Insiders  2.43 %  
Shares Owned by Institutions  92.15 %  
Number of Shares Shorted  3.71 M  
Price to Earning  (6.56) X  
Price to Book  7.11 X  
Price to Sales  54.98 X  
Revenue  102.92 M  
Gross Profit  (13.08 M)  
EBITDA  (304.55 M)  
Net Income  (303.5 M)  
Cash and Equivalents  771.85 M  
Cash per Share  8.18 X  
Total Debt  24.39 M  
Debt to Equity  0.03 %  
Current Ratio  14.36 X  
Book Value Per Share  8.43 X  
Cash Flow from Operations  (294.63 M)  
Short Ratio  4.79 X  
Earnings Per Share  (3.61) X  
Price to Earnings To Growth  (0.09) X  
Number of Employees  512  
Beta  1.13  
Market Capitalization  5.66 B  
Total Asset  542.57 M  
Retained Earnings  (728.79 M)  
Working Capital  401.13 M  
Current Asset  541.82 M  
Current Liabilities  140.69 M 
About IntraCellular Ther Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IntraCellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IntraCellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IntraCellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.IntraCellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. IntraCellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. IntraCellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in IntraCellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes 
All Next  Launch Module 
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as IntraCellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please see IntraCellular Ther Piotroski F Score and IntraCellular Ther Valuation analysis. Note that the IntraCellular Ther information on this page should be used as a complementary analysis to other IntraCellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for IntraCellular Stock analysis
When running IntraCellular Ther price analysis, check to measure IntraCellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IntraCellular Ther is operating at the current time. Most of IntraCellular Ther's value examination focuses on studying past and present price action to predict the probability of IntraCellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move IntraCellular Ther's price. Additionally, you may evaluate how the addition of IntraCellular Ther to your portfolios can decrease your overall portfolio volatility.
Bond DirectoryFind actively traded corporate debentures issued by US companies  Go  
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and riskadjusted market performance  Go  
Money ManagersScreen money managers from public funds and ETFs managed around the world  Go  
Focused OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences  Go  
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios  Go  
Transaction HistoryView history of all your transactions and understand their impact on performance  Go  
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk  Go  
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account  Go  
Performance AnalysisCheck effects of meanvariance optimization against your current asset allocation  Go  
Volatility AnalysisGet historical volatility and risk analysis based on latest market data  Go  
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios  Go 
Is IntraCellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IntraCellular Ther. If investors know IntraCellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IntraCellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 5.3 B  Quarterly Revenue Growth YOY 1.2  Return On Assets 0.25  Return On Equity 0.43 
The market value of IntraCellular Ther is measured differently than its book value, which is the value of IntraCellular that is recorded on the company's balance sheet. Investors also form their own opinion of IntraCellular Ther's value that differs from its market value or its book value, called intrinsic value, which is IntraCellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IntraCellular Ther's market value can be influenced by many factors that don't directly affect IntraCellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IntraCellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine IntraCellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IntraCellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.